BioXcel Therapeutics, Inc. (BTAI) 10-Year Financial Performance & Capital Metrics

BTAI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Show more

Revenue $2M +64.2%
EBITDA -$67M +61.0%
Net Income -$60M +66.7%
EPS (Diluted) -23.51 +76.1%
Gross Margin 5.43% -37.6%
EBITDA Margin -2953.93% +76.2%
Operating Margin -2967.56% +76.2%
Net Margin -2630.14% +79.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -4.44 +65.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 39.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-66.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM71.83%

ROCE

10Y Avg-111.02%

5Y Avg-114.24%

3Y Avg-150.78%

Latest-215.05%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	375K	1.38M	2.27M
Revenue Growth %	-	-	-	-	-	-	-	2.68%	0.64%
Cost of Goods Sold+	0	1K	17K	156K	0	297K	20K	1.26M	2.14M
COGS % of Revenue	-	-	-	-	-	-	0.05%	0.91%	0.95%
Gross Profit+	0	-1K	-17K	-156K	0	-297K	355K	120K	123K
Gross Margin %	-	-	-	-	-	-	0.95%	0.09%	0.05%
Gross Profit Growth %	-	-	-16%	-8.18%	1%	-	2.2%	-0.66%	0.03%
Operating Expenses+	2.12M	4.54M	19.96M	33.6M	82.3M	105.6M	160M	171.9M	67.37M
OpEx % of Revenue	-	-	-	-	-	-	426.67%	124.57%	29.73%
Selling, General & Admin	721K	1.85M	5.4M	7.8M	24.65M	54.01M	68.76M	83.41M	34.49M
SG&A % of Revenue	-	-	-	-	-	-	183.36%	60.44%	15.22%
Research & Development	1.4M	2.69M	14.56M	25.8M	58.54M	51.59M	91.24M	84.33M	30.43M
R&D % of Revenue	-	-	-	-	-	-	243.3%	61.11%	13.43%
Other Operating Expenses	0	0	0	0	-888K	0	0	4.16M	2.44M
Operating Income+	-2.12M	-4.54M	-19.96M	-33.6M	-82.3M	-105.89M	-159.65M	-171.78M	-67.25M
Operating Margin %	-	-	-	-	-	-	-425.72%	-124.48%	-29.68%
Operating Income Growth %	-	-1.14%	-3.4%	-0.68%	-1.45%	-0.29%	-0.51%	-0.08%	0.61%
EBITDA+	0	-4.54M	-19.95M	-33.45M	-82.11M	-105.6M	-159.32M	-171.46M	-66.94M
EBITDA Margin %	-	-	-	-	-	-	-424.85%	-124.25%	-29.54%
EBITDA Growth %	-	-	-3.4%	-0.68%	-1.46%	-0.29%	-0.51%	-0.08%	0.61%
D&A (Non-Cash Add-back)	2.12M	1K	17K	156K	188K	297K	327K	318K	309K
EBIT	-2.12M	-4.54M	-19.27M	-32.97M	-82.3M	-107.29M	-157.54M	-165.74M	-44.47M
Net Interest Income+	0	-2K	0	633K	128K	-36K	-5.68M	-7.67M	-12.53M
Interest Income	0	0	0	633K	155K	4K	2.53M	5.65M	2.6M
Interest Expense	0	2K	0	0	27K	40K	8.21M	13.31M	15.13M
Other Income/Expense	0	-2K	692K	633K	128K	-1.4M	-6.11M	-7.27M	7.65M
Pretax Income+	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-107.29M	-165.76M	-179.05M	-59.6M
Pretax Margin %	-	-	-	-	-	-	-442.02%	-129.75%	-26.3%
Income Tax+	0	0	0	0	0	-362K	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-2.12M	-4.54M	-19.27M	-32.34M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Net Margin %	-	-	-	-	-	-	-442.02%	-129.75%	-26.3%
Net Income Growth %	-	-1.14%	-3.25%	-0.68%	-1.54%	-0.3%	-0.55%	-0.08%	0.67%
Net Income (Continuing)	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.06	-4.41	-21.16	-32.38	-60.63	-64.87	-94.67	-98.35	-23.51
EPS Growth %	-	-1.14%	-3.8%	-0.53%	-0.87%	-0.07%	-0.46%	-0.04%	0.76%
EPS (Basic)	-2.06	-4.41	-21.16	-32.38	-60.63	-64.87	-94.67	-98.35	-23.51
Diluted Shares Outstanding	1.03M	1.03M	910.72K	1.02M	1.36M	1.65M	1.75M	1.82M	2.54M
Basic Shares Outstanding	1.03M	1.03M	910.72K	1.02M	1.36M	1.65M	1.75M	1.82M	2.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2K	890K	43.17M	34.11M	217.06M	236.81M	202.87M	72.14M	37.39M
Cash & Short-Term Investments	0	887K	42.56M	32.43M	213.12M	232.97M	193.72M	65.22M	29.85M
Cash Only	0	887K	42.56M	32.43M	213.12M	232.97M	193.72M	65.22M	29.85M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	115K	0	0	0	248K	71K	131K
Days Sales Outstanding	-	-	-	-	-	-	241.39	18.78	21.1
Inventory	0	0	0	0	0	0	1.99M	1.99M	679K
Days Inventory Outstanding	-	-	-	-	-	-	36.23K	576.76	115.65
Other Current Assets	0	0	0	0	984K	956K	3.84M	2.08M	1.44M
Total Non-Current Assets+	5K	465K	378K	2.29M	2.87M	2.63M	2.98M	1.56M	944K
Property, Plant & Equipment	5K	4K	327K	2.23M	2.78M	2.54M	2.06M	1.47M	857K
Fixed Asset Turnover	-	-	-	-	-	-	0.18x	0.94x	2.64x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	461K	51K	51K	87K	86K	925K	87K	87K
Total Assets+	7K	1.35M	43.55M	36.39M	219.94M	239.44M	205.85M	73.7M	38.34M
Asset Turnover	-	-	-	-	-	-	0.00x	0.02x	0.06x
Asset Growth %	-	192.57%	31.14%	-0.16%	5.04%	0.09%	-0.14%	-0.64%	-0.48%
Total Current Liabilities+	331K	2.34M	4.66M	8.47M	11.84M	16.67M	32.9M	27.27M	22.23M
Accounts Payable	279K	444K	1.6M	4.95M	3.98M	4.68M	10.23M	13.65M	15.99M
Days Payables Outstanding	-	162.06K	34.44K	11.59K	-	5.75K	186.66K	3.96K	2.72K
Short-Term Debt	0	371K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	-164K	0	0	0	0	0
Other Current Liabilities	0	0	0	2.04M	2.07M	3.97M	6.46M	163K	142K
Current Ratio	0.01x	0.38x	9.26x	4.03x	18.33x	14.21x	6.17x	2.65x	1.68x
Quick Ratio	0.01x	0.38x	9.26x	4.03x	18.33x	14.21x	6.11x	2.57x	1.65x
Cash Conversion Cycle	-	-	-	-	-	-	-150.19K	-3.36K	-2.59K
Total Non-Current Liabilities+	0	0	0	1.03M	1.4M	1.1M	96.18M	102.94M	109.21M
Long-Term Debt	0	0	0	0	0	0	93.05M	100.6M	102.51M
Capital Lease Obligations	0	0	0	1.03M	1.4M	1.1M	786K	440K	65K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	2.34M	1.91M	6.63M
Total Liabilities	331K	2.34M	4.66M	9.5M	13.24M	17.77M	129.08M	130.21M	131.44M
Total Debt+	0	371K	0	1.03M	1.64M	1.4M	94.16M	101.38M	102.95M
Net Debt	0	-516K	-42.56M	-31.4M	-211.48M	-231.57M	-99.57M	36.16M	73.09M
Debt / Equity	-	-	-	0.04x	0.01x	0.01x	1.23x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-2268.50x	-	-	-3048.04x	-2647.38x	-19.44x	-12.90x	-4.44x
Total Equity+	-324K	-982K	38.89M	26.89M	206.7M	221.67M	76.78M	-56.51M	-93.1M
Equity Growth %	-	-2.03%	40.6%	-0.31%	6.69%	0.07%	-0.65%	-1.74%	-0.65%
Book Value per Share	-0.31	-0.95	42.70	26.42	152.52	134.48	43.85	-31.04	-36.73
Total Shareholders' Equity	-324K	-982K	38.89M	26.89M	206.7M	221.67M	76.78M	-56.51M	-93.1M
Common Stock	0	10K	16K	18K	24K	28K	28K	30K	49K
Retained Earnings	0	-4.45M	-23.72M	-56.69M	-138.86M	-245.79M	-411.55M	-590.6M	-650.2M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-1K	-18K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.29M	-2.2M	-13.51M	-27.28M	-66.35M	-82.15M	-135.34M	-155.01M	-72.03M
Operating CF Margin %	-	-	-	-	-	-	-360.91%	-112.32%	-31.79%
Operating CF Growth %	-	-0.7%	-5.15%	-1.02%	-1.43%	-0.24%	-0.65%	-0.15%	0.54%
Net Income	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Depreciation & Amortization	0	1K	17K	156K	188K	297K	327K	318K	309K
Stock-Based Compensation	671K	1.61M	3.08M	3.14M	14.61M	19.45M	17.34M	18.61M	6.16M
Deferred Taxes	0	0	0	-3.45M	-14.99M	0	0	0	0
Other Non-Cash Items	671K	1.61M	3.12M	3.45M	14.99M	46K	2.35M	3.1M	-12.86M
Working Capital Changes	155K	736K	2.66M	2.39M	1.02M	4.98M	10.4M	2.02M	-6.03M
Change in Receivables	0	0	0	0	0	0	-248K	177K	-60K
Change in Inventory	0	0	0	0	0	0	-1.99M	-6K	1.31M
Change in Payables	156K	737K	3.2M	3.58M	3.03M	4.85M	13.03M	-3.22M	-4.33M
Cash from Investing+	-4K	0	-340K	-870K	-316K	-445K	-139K	-20K	0
Capital Expenditures	-4K	0	-340K	-870K	-316K	-445K	-139K	-20K	0
CapEx % of Revenue	-	-	-	-	-	-	0.37%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-340K	0	0	0	0	0	0
Cash from Financing+	1.3M	3.08M	55.53M	18.01M	247.36M	102.45M	96.24M	26.52M	36.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	1.3M	584K	-615K	201K	598K	1.45M	-2.36M	-510K	-528K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.3M	-2.2M	-13.85M	-28.15M	-66.67M	-82.6M	-135.48M	-155.03M	-72.03M
FCF Margin %	-	-	-	-	-	-	-361.28%	-112.34%	-31.79%
FCF Growth %	-	-0.69%	-5.31%	-1.03%	-1.37%	-0.24%	-0.64%	-0.14%	0.54%
FCF per Share	-1.26	-2.13	-15.21	-27.65	-49.19	-50.11	-77.38	-85.15	-28.41
FCF Conversion (FCF/Net Income)	0.61x	0.48x	0.70x	0.84x	0.81x	0.77x	0.82x	0.87x	1.21x
Interest Paid	0	0	0	0	0	0	2.7M	7.55M	7.97M
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-101.67%	-98.31%	-70.35%	-49.93%	-111.08%	-1766.94%	-
Gross Margin	-	-	-	-	-	-	94.67%	8.7%	5.43%
Net Margin	-	-	-	-	-	-	-44201.87%	-12974.86%	-2630.14%
Debt / Equity	-	-	-	0.04x	0.01x	0.01x	1.23x	-	-
Interest Coverage	-	-2268.50x	-	-	-3048.04x	-2647.38x	-19.44x	-12.90x	-4.44x
FCF Conversion	0.61x	0.48x	0.70x	0.84x	0.81x	0.77x	0.82x	0.87x	1.21x
Revenue Growth	-	-	-	-	-	-	-	268%	64.2%

Frequently Asked Questions

Growth & Financials

BioXcel Therapeutics, Inc. (BTAI) reported $0.8M in revenue for fiscal year 2024.

BioXcel Therapeutics, Inc. (BTAI) grew revenue by 64.2% over the past year. This is strong growth.

BioXcel Therapeutics, Inc. (BTAI) reported a net loss of $68.2M for fiscal year 2024.

Dividend & Returns

BioXcel Therapeutics, Inc. (BTAI) had negative free cash flow of $58.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BioXcel Therapeutics, Inc. (BTAI) 10-Year Financial Performance & Capital Metrics

BTAI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $2M +64.2%
EBITDA -$67M +61.0%
Net Income -$60M +66.7%
EPS (Diluted) -23.51 +76.1%
Gross Margin 5.43% -37.6%
EBITDA Margin -2953.93% +76.2%
Operating Margin -2967.56% +76.2%
Net Margin -2630.14% +79.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -4.44 +65.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 39.2% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-66.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM3.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM71.83%

ROCE

10Y Avg-111.02%

5Y Avg-114.24%

3Y Avg-150.78%

Latest-215.05%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	375K	1.38M	2.27M
Revenue Growth %	-	-	-	-	-	-	-	2.68%	0.64%
Cost of Goods Sold+	0	1K	17K	156K	0	297K	20K	1.26M	2.14M
COGS % of Revenue	-	-	-	-	-	-	0.05%	0.91%	0.95%
Gross Profit+	0	-1K	-17K	-156K	0	-297K	355K	120K	123K
Gross Margin %	-	-	-	-	-	-	0.95%	0.09%	0.05%
Gross Profit Growth %	-	-	-16%	-8.18%	1%	-	2.2%	-0.66%	0.03%
Operating Expenses+	2.12M	4.54M	19.96M	33.6M	82.3M	105.6M	160M	171.9M	67.37M
OpEx % of Revenue	-	-	-	-	-	-	426.67%	124.57%	29.73%
Selling, General & Admin	721K	1.85M	5.4M	7.8M	24.65M	54.01M	68.76M	83.41M	34.49M
SG&A % of Revenue	-	-	-	-	-	-	183.36%	60.44%	15.22%
Research & Development	1.4M	2.69M	14.56M	25.8M	58.54M	51.59M	91.24M	84.33M	30.43M
R&D % of Revenue	-	-	-	-	-	-	243.3%	61.11%	13.43%
Other Operating Expenses	0	0	0	0	-888K	0	0	4.16M	2.44M
Operating Income+	-2.12M	-4.54M	-19.96M	-33.6M	-82.3M	-105.89M	-159.65M	-171.78M	-67.25M
Operating Margin %	-	-	-	-	-	-	-425.72%	-124.48%	-29.68%
Operating Income Growth %	-	-1.14%	-3.4%	-0.68%	-1.45%	-0.29%	-0.51%	-0.08%	0.61%
EBITDA+	0	-4.54M	-19.95M	-33.45M	-82.11M	-105.6M	-159.32M	-171.46M	-66.94M
EBITDA Margin %	-	-	-	-	-	-	-424.85%	-124.25%	-29.54%
EBITDA Growth %	-	-	-3.4%	-0.68%	-1.46%	-0.29%	-0.51%	-0.08%	0.61%
D&A (Non-Cash Add-back)	2.12M	1K	17K	156K	188K	297K	327K	318K	309K
EBIT	-2.12M	-4.54M	-19.27M	-32.97M	-82.3M	-107.29M	-157.54M	-165.74M	-44.47M
Net Interest Income+	0	-2K	0	633K	128K	-36K	-5.68M	-7.67M	-12.53M
Interest Income	0	0	0	633K	155K	4K	2.53M	5.65M	2.6M
Interest Expense	0	2K	0	0	27K	40K	8.21M	13.31M	15.13M
Other Income/Expense	0	-2K	692K	633K	128K	-1.4M	-6.11M	-7.27M	7.65M
Pretax Income+	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-107.29M	-165.76M	-179.05M	-59.6M
Pretax Margin %	-	-	-	-	-	-	-442.02%	-129.75%	-26.3%
Income Tax+	0	0	0	0	0	-362K	0	0	0
Effective Tax Rate %	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-2.12M	-4.54M	-19.27M	-32.34M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Net Margin %	-	-	-	-	-	-	-442.02%	-129.75%	-26.3%
Net Income Growth %	-	-1.14%	-3.25%	-0.68%	-1.54%	-0.3%	-0.55%	-0.08%	0.67%
Net Income (Continuing)	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.06	-4.41	-21.16	-32.38	-60.63	-64.87	-94.67	-98.35	-23.51
EPS Growth %	-	-1.14%	-3.8%	-0.53%	-0.87%	-0.07%	-0.46%	-0.04%	0.76%
EPS (Basic)	-2.06	-4.41	-21.16	-32.38	-60.63	-64.87	-94.67	-98.35	-23.51
Diluted Shares Outstanding	1.03M	1.03M	910.72K	1.02M	1.36M	1.65M	1.75M	1.82M	2.54M
Basic Shares Outstanding	1.03M	1.03M	910.72K	1.02M	1.36M	1.65M	1.75M	1.82M	2.54M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2K	890K	43.17M	34.11M	217.06M	236.81M	202.87M	72.14M	37.39M
Cash & Short-Term Investments	0	887K	42.56M	32.43M	213.12M	232.97M	193.72M	65.22M	29.85M
Cash Only	0	887K	42.56M	32.43M	213.12M	232.97M	193.72M	65.22M	29.85M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	115K	0	0	0	248K	71K	131K
Days Sales Outstanding	-	-	-	-	-	-	241.39	18.78	21.1
Inventory	0	0	0	0	0	0	1.99M	1.99M	679K
Days Inventory Outstanding	-	-	-	-	-	-	36.23K	576.76	115.65
Other Current Assets	0	0	0	0	984K	956K	3.84M	2.08M	1.44M
Total Non-Current Assets+	5K	465K	378K	2.29M	2.87M	2.63M	2.98M	1.56M	944K
Property, Plant & Equipment	5K	4K	327K	2.23M	2.78M	2.54M	2.06M	1.47M	857K
Fixed Asset Turnover	-	-	-	-	-	-	0.18x	0.94x	2.64x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	461K	51K	51K	87K	86K	925K	87K	87K
Total Assets+	7K	1.35M	43.55M	36.39M	219.94M	239.44M	205.85M	73.7M	38.34M
Asset Turnover	-	-	-	-	-	-	0.00x	0.02x	0.06x
Asset Growth %	-	192.57%	31.14%	-0.16%	5.04%	0.09%	-0.14%	-0.64%	-0.48%
Total Current Liabilities+	331K	2.34M	4.66M	8.47M	11.84M	16.67M	32.9M	27.27M	22.23M
Accounts Payable	279K	444K	1.6M	4.95M	3.98M	4.68M	10.23M	13.65M	15.99M
Days Payables Outstanding	-	162.06K	34.44K	11.59K	-	5.75K	186.66K	3.96K	2.72K
Short-Term Debt	0	371K	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	-164K	0	0	0	0	0
Other Current Liabilities	0	0	0	2.04M	2.07M	3.97M	6.46M	163K	142K
Current Ratio	0.01x	0.38x	9.26x	4.03x	18.33x	14.21x	6.17x	2.65x	1.68x
Quick Ratio	0.01x	0.38x	9.26x	4.03x	18.33x	14.21x	6.11x	2.57x	1.65x
Cash Conversion Cycle	-	-	-	-	-	-	-150.19K	-3.36K	-2.59K
Total Non-Current Liabilities+	0	0	0	1.03M	1.4M	1.1M	96.18M	102.94M	109.21M
Long-Term Debt	0	0	0	0	0	0	93.05M	100.6M	102.51M
Capital Lease Obligations	0	0	0	1.03M	1.4M	1.1M	786K	440K	65K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	2.34M	1.91M	6.63M
Total Liabilities	331K	2.34M	4.66M	9.5M	13.24M	17.77M	129.08M	130.21M	131.44M
Total Debt+	0	371K	0	1.03M	1.64M	1.4M	94.16M	101.38M	102.95M
Net Debt	0	-516K	-42.56M	-31.4M	-211.48M	-231.57M	-99.57M	36.16M	73.09M
Debt / Equity	-	-	-	0.04x	0.01x	0.01x	1.23x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-2268.50x	-	-	-3048.04x	-2647.38x	-19.44x	-12.90x	-4.44x
Total Equity+	-324K	-982K	38.89M	26.89M	206.7M	221.67M	76.78M	-56.51M	-93.1M
Equity Growth %	-	-2.03%	40.6%	-0.31%	6.69%	0.07%	-0.65%	-1.74%	-0.65%
Book Value per Share	-0.31	-0.95	42.70	26.42	152.52	134.48	43.85	-31.04	-36.73
Total Shareholders' Equity	-324K	-982K	38.89M	26.89M	206.7M	221.67M	76.78M	-56.51M	-93.1M
Common Stock	0	10K	16K	18K	24K	28K	28K	30K	49K
Retained Earnings	0	-4.45M	-23.72M	-56.69M	-138.86M	-245.79M	-411.55M	-590.6M	-650.2M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	-1K	-18K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.29M	-2.2M	-13.51M	-27.28M	-66.35M	-82.15M	-135.34M	-155.01M	-72.03M
Operating CF Margin %	-	-	-	-	-	-	-360.91%	-112.32%	-31.79%
Operating CF Growth %	-	-0.7%	-5.15%	-1.02%	-1.43%	-0.24%	-0.65%	-0.15%	0.54%
Net Income	-2.12M	-4.54M	-19.27M	-32.97M	-82.17M	-106.93M	-165.76M	-179.05M	-59.6M
Depreciation & Amortization	0	1K	17K	156K	188K	297K	327K	318K	309K
Stock-Based Compensation	671K	1.61M	3.08M	3.14M	14.61M	19.45M	17.34M	18.61M	6.16M
Deferred Taxes	0	0	0	-3.45M	-14.99M	0	0	0	0
Other Non-Cash Items	671K	1.61M	3.12M	3.45M	14.99M	46K	2.35M	3.1M	-12.86M
Working Capital Changes	155K	736K	2.66M	2.39M	1.02M	4.98M	10.4M	2.02M	-6.03M
Change in Receivables	0	0	0	0	0	0	-248K	177K	-60K
Change in Inventory	0	0	0	0	0	0	-1.99M	-6K	1.31M
Change in Payables	156K	737K	3.2M	3.58M	3.03M	4.85M	13.03M	-3.22M	-4.33M
Cash from Investing+	-4K	0	-340K	-870K	-316K	-445K	-139K	-20K	0
Capital Expenditures	-4K	0	-340K	-870K	-316K	-445K	-139K	-20K	0
CapEx % of Revenue	-	-	-	-	-	-	0.37%	0.01%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-340K	0	0	0	0	0	0
Cash from Financing+	1.3M	3.08M	55.53M	18.01M	247.36M	102.45M	96.24M	26.52M	36.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	1.3M	584K	-615K	201K	598K	1.45M	-2.36M	-510K	-528K
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.3M	-2.2M	-13.85M	-28.15M	-66.67M	-82.6M	-135.48M	-155.03M	-72.03M
FCF Margin %	-	-	-	-	-	-	-361.28%	-112.34%	-31.79%
FCF Growth %	-	-0.69%	-5.31%	-1.03%	-1.37%	-0.24%	-0.64%	-0.14%	0.54%
FCF per Share	-1.26	-2.13	-15.21	-27.65	-49.19	-50.11	-77.38	-85.15	-28.41
FCF Conversion (FCF/Net Income)	0.61x	0.48x	0.70x	0.84x	0.81x	0.77x	0.82x	0.87x	1.21x
Interest Paid	0	0	0	0	0	0	2.7M	7.55M	7.97M
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-101.67%	-98.31%	-70.35%	-49.93%	-111.08%	-1766.94%	-
Gross Margin	-	-	-	-	-	-	94.67%	8.7%	5.43%
Net Margin	-	-	-	-	-	-	-44201.87%	-12974.86%	-2630.14%
Debt / Equity	-	-	-	0.04x	0.01x	0.01x	1.23x	-	-
Interest Coverage	-	-2268.50x	-	-	-3048.04x	-2647.38x	-19.44x	-12.90x	-4.44x
FCF Conversion	0.61x	0.48x	0.70x	0.84x	0.81x	0.77x	0.82x	0.87x	1.21x
Revenue Growth	-	-	-	-	-	-	-	268%	64.2%

Frequently Asked Questions

Growth & Financials

BioXcel Therapeutics, Inc. (BTAI) reported $0.8M in revenue for fiscal year 2024.

BioXcel Therapeutics, Inc. (BTAI) grew revenue by 64.2% over the past year. This is strong growth.

BioXcel Therapeutics, Inc. (BTAI) reported a net loss of $68.2M for fiscal year 2024.

Dividend & Returns

BioXcel Therapeutics, Inc. (BTAI) had negative free cash flow of $58.2M in fiscal year 2024, likely due to heavy capital investments.